STAGE IV MAJOR SALIVARY GLAND CANCER AJCC V8
Clinical trials for STAGE IV MAJOR SALIVARY GLAND CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV MAJOR SALIVARY GLAND CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IV MAJOR SALIVARY GLAND CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to shrink Hard-to-Treat salivary gland tumors
Disease control OngoingThis study tests whether combining the chemotherapy drug pemetrexed with the immunotherapy drug pembrolizumab can shrink or control advanced salivary gland cancer that has returned or spread. About 45 adults with this rare cancer will receive both drugs intravenously. The goal is…
Matched conditions: STAGE IV MAJOR SALIVARY GLAND CANCER AJCC V8
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 12, 2026 13:42 UTC
-
New combo therapy targets hard-to-treat HER2 cancers in early trial
Disease control OngoingThis early-phase trial tests a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a cell-growth blocker)—in people with advanced solid tumors that have a HER2 mutation. The study first finds the safest dose, then compares the combo against…
Matched conditions: STAGE IV MAJOR SALIVARY GLAND CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 06, 2026 16:02 UTC